Former U.S. ambassador to the World Trade Organization Dennis Shea says a planned discussion at the WTO about matters that affect trade in cotton “must examine the trade impact of the use of forced labor to pick cotton in China’s Xinjiang province.” Shea, who was writing for the Center for Strategic and International Studies, where he is now an adjunct fellow, said “ignoring what is happening in Xinjiang would be tantamount to the WTO holding a meeting on global public health and trade without mentioning the Covid-19 pandemic. ... The use of forced labor in the province has likely depressed the global price of cotton, adversely impacted other cotton-exporting nations (particularly those in the developing world) and improperly distorted global trade flows,” and may even be a countervailable subsidy. Shea said the U.S. should raise the issue during the late May meeting.
The U.S. praised Vietnam for its role in the World Trade Organization fisheries negotiations and its fight against transshipment, but said it has concerns about sanitary and phytosanitary measures in Vietnam that in the U.S. view are unwarranted barriers to trade.
Even as the U.S. and the European Union work privately to resolve their differences over subsidies to Airbus and Boeing, a U.S. representative at the World Trade Organization complained that the EU provided no status update on coming into compliance over Airbus subsidies. The EU said that the measures it took in August 2020 (see 2008280051) were more than enough to comply with a WTO ruling, according to a Geneva trade official.
U.S. Trade Representative Katherine Tai published a readout of video calls she had with the leader of AstraZeneca's U.S. business and Pfizer's CEO on whether there should be a waiver of the World Trade Organization's agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). The readouts did not say what either the government or companies' positions are on a TRIPS waiver, and during a background call on aid to India to combat its surge of cases and deaths, an official also sidestepped a question on the waiver. The readouts said that Tai “emphasized her commitment to working with WTO members on a global pandemic response, including the role of developing countries in any effective solution that addresses critical gaps in global production and distribution of vaccines”; and that the Pfizer CEO also wants to improve global access to the vaccine, and he discussed “how trade policy could help address the challenges of increasing vaccine production and distribution around the world.”
U.S. Trade Representative Katherine Tai heard from 16 unions, UNITE HERE and the AFL-CIO on their wish for the U.S. to drop its opposition to a Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement waiver for COVID-19 vaccines (see 2102260053). In a readout of the April 13 online meeting, the agency said: “Ambassador Tai reiterated that the Biden-Harris Administration’s top priority is saving lives and ending the pandemic in the United States and around the world. The Ambassador conveyed the Administration’s commitment to increasing Covid-19 vaccine production and distribution, both at home and worldwide.”
Many advocates for developing countries say a TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights) waiver is needed to accelerate access to vaccines, treatments and COVID-19 tests, but most speakers at an American Bar Association-convened panel said that countries already have the power to curtail pharmaceutical patents for a pandemic, and that technical knowledge and input shortages are a bigger barrier than patents.
Four intellectual property industry groups, in a letter to U.S. Trade Representative Katherine Tai, voiced their support for the U.S.'s opposition to the TRIPS waiver at the World Trade Organization. The American Intellectual Property Law Association, Intellectual Property Owners Association, the Licensing Executives Society (USA and Canada) Inc. and the New York Intellectual Property Law Association said they wrote to protect the IP rights of their members that have incentivized the innovations that “allowed us to combat COVID-19 and continues to do so.” The TRIPS waiver would waive IP rights relating to the “prevention, containment or treatment” of the novel coronavirus for a limited period of time. The industry groups argue that it has been IP itself that has allowed for life-saving innovations and facilitated the sharing of technical information with appropriate protections. They also suggest that they know of no data that shows IP rights are restricting vaccine development.
A top European Commission trade official said that it's not reasonable to expect that countries can agree on reforms to dispute settlement that would satisfy the U.S. by November this year. So, Ignacio Garcia Bercero said, countries will need to set a goal of restoring the binding dispute settlement system for the 2023 ministerial meeting of the World Trade Organization. “The WTO without binding dispute settlement is not the WTO,” Garcia Bercero said during a presentation online at the Peterson Institute for International Economics on March 19. “The continued escalation of conflicts if we don’t have a functioning dispute settlement system should be something we should all be worried about.”
A former World Trade Organization appellate body member and a longtime U.S. trade representative's environment advisory committee member agree that an attempt to create a carbon adjustment mechanism by the European Union is likely to violate trade law and support protectionist aims.
The Office of the U.S. Trade Representative is seeking comments on the complaint that Hong Kong has raised at the World Trade Organization by April 12. The territory of Hong Kong has said that the U.S. is breaking WTO rules by requiring that exporters mark goods from Hong Kong as Made in China, rather than Made in Hong Kong. The U.S. issued an executive order last year making the change because of China's political crackdown against Hong Kong. The marking rule does not affect tariff treatment (see 2008130028).